TISSEEL
ApprovedSmall molecule
TISSEEL is one of 38 small molecule programs targeting Cleft Palate. It is currently in Approved.
4
Indications
10
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
41 competitors in Rotator Cuff Tear
#DrugCompanyPhaseTrials
1Depo-Testosterone
AAzurity Pharmaceuticals
Approved
Naropin
FFresenius Kabi Oncology Ltd.
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Suboxone
IIndivior Inc.
Approved
Tylenol
KKenvue Brands
Approved
Marcaine
IInnocoll
Approved
Decadron
AAspen Global Incorporated
Approved
Valium
Akero TherapeuticsApproved
Neurontin
VViatris Specialty LLC
Approved
IC-Green
CCHX Technologies Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Randomized1 trial
A Randomized Trial of CT Fluoroscopy-guided Targeted Autologous Blood and Fibrin Glue Patching for Treatment
Completed·—·Phase 2·NCT03276975·15 enrolled
Blood Loss1 trial
Reducing Blood Loss Using Tisseel in TKA
Unknown status·—·Phase 4·NCT03310060·100 enrolled
5 more indications
Rotator Cuff Tear1 trial
Surgical1 trial
Complication1 trial
Efficiency of TISSEEL for Sleeve Gastrectomy Complications
Completed·—·Phase 3·NCT01613664·597 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TISSEEL. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity Hospital, Ghent